Table 3

Treatment-related adverse events

Adverse event, n(%)Grade 1–2 (%)Grade 3 (%)Grade 4 (%)
Dysphonia 36 (67)0 (0)0 (0)
Lymphopenia 25 (46)2 (4)0 (0)
Diarrhea 24 (44)2 (4)0 (0)
Hypertension 22 (41)4 (7)0 (0)
Fatigue 21 (39)4 (7)0 (0)
Thrombocytopenia 24 (44)1 (2)0 (0)
Erythrocytosis 18 (33)0 (0)0 (0)
Thyroid-stimulating hormone increase 15 (28)1 (2)0 (0)
Alanine aminotransferase increase 13 (24)1 (2)0 (0)
Mucositis/aphtosis 13 (24)0 (0)0 (0)
Neutrophilia 9 (17)0 (0)0 (0)
Aspartate aminotransferase increase 8 (15)1 (2)0 (0)
Gamma-glutamyltransferase increase 4 (7)5 (9)0 (0)
Anorexia 7 (13)1 (2)0 (0)
Alkaline phosphatase increase 6 (11)0 (0)0 (0)
Headache 6 (11)0 (0)0 (0)
Chills-acute infusion reaction 6 (11)0 (0)0 (0)
Oral dysesthesia 5 (9)0 (0)0 (0)
Pruritus 5 (9)0 (0)0 (0)
Fever-acute infusion reaction 5 (9)0 (0)0 (0)
Dry mouth 4 (7)0 (0)0 (0)
Arthralgia 4 (7)0 (0)0 (0)
Abdominal pain 4 (7)0 (0)0 (0)
Rash papulopustular 4 (7)0 (0)0 (0)
Eosinophilia 4 (7)0 (0)0 (0)
Pulmonary embolism 0 (0)0 (0)3 (6)
Rash 3 (6)0 (0)0 (0)
Nausea 3 (6)0 (0)0 (0)
Confusion 2 (4)1 (2)0 (0)
Constipation 3 (6)0 (0)0 (0)
Thyroid-stimulating hormone decrease 3 (6)0 (0)0 (0)
Dyspnea 1 (2)1 (2)0 (0)
Hepatitis 1 (2)1 (2)0 (0)
Myalgia 2 (4)0 (0)0 (0)
Periodontal disease 2 (4)0 (0)0 (0)
Rash seborrheic 2 (4)0 (0)0 (0)
Rhinitis 2 (4)0 (0)0 (0)
Urinary frequency 2 (4)0 (0)0 (0)
Neutropenia 2 (4)0 (0)0 (0)
Creatine kinase increase 1 (2)1 (2)0 (0)
Acute kidney injury 0 (0)1 (2)0 (0)
Hypothyroidism 1 (2)0 (0)0 (0)
Dysphagia 1 (2)0 (0)0 (0)
Erythema 1 (2)0 (0)0 (0)
Impaired consciousness 0 (0)1 (2)0 (0)
Intracranial hemorrhage 0 (0)1 (2)0 (0)
Petechiae 1 (2)0 (0)0 (0)
Pneumonitis 0 (0)1 (2)0 (0)
Rash maculopapular 1 (2)0 (0)0 (0)
Rash psoriasiform 1 (2)0 (0)0 (0)
Subcutaneous swelling 1 (2)0 (0)0 (0)
Microscopic colitis 1 (2)0 (0)0 (0)
Vomiting 1 (2)0 (0)0 (0)
Lymphocytosis 1 (2)0 (0)0 (0)
Xerophtalmia 1 (2)0 (0)0 (0)
Xerosis 1 (2)0 (0)0 (0)